Skip to main content

Fiscal Wizard · Single-issue tearsheet

RXRX / Jun 21, 2026 Run #7306

RXRX

Recursion Pharmaceuticals, Inc.

Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Composite verdict

F 19.4 / 100
Bearish setup · Trend Following 10 drivers · 6 gates blocking
  • Rate of Change
  • Coppock Curve
  • Accumulation/Distribution Line
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 278th of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: volatile range
Bull 0%Evidence: High · 16 signals100% Bear
Momentum Bearish 2Mean-reversion Neutral 49

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes from

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Weak

38.8 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Days Sales Outstanding 100
Free Cash Flow Yield 0
Revenue Growth (YoY) 100
P/S Ratio 25
P/B 75
EV/Sales 25

Technicals Bearish

0.1 / 100

Bearish setup leads (Rate of Change, Coppock Curve, Accumulation/Distribution Line); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Rate of Change 8
Accumulation/Distribution Line 10
Coppock Curve 12

Risk Gates

6 blocking 5 caution

6 guards active, 24 signals gated.

Altman Z-Score Blocking

Bottom-band Altman Z blocks bullish signals — distress risk.

Interest Coverage Blocking

Weak interest coverage blocks bullish signals — debt-service risk.

ADX Trend Weakness Blocking

Weak trend strength blocks trend-following signals in either direction.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for RXRX.